Integrated Analysis Of Genome, Epigenome, And Transcriptome Data In Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$417,511.00
Summary
Schizophrenia is a severe psychiatric disorder with a diverse range of symptoms. While the cause is unknown, it is thought to develop from a combination of genetic, epigenetic and environmental risk factors. This study will use genome wide approaches to investigate the relationship between genetic/epigenetic modification of DNA and gene expression in schizophrenia. This study could provide an integrated understanding of the neuropathology of schizophrenia and ultimately lead to better treatment.
A New Animal Model Of The Prodrome In Schizophrenia. Enhanced Dopamine In Prodromal Schizophrenia (EDiPs)
Funder
National Health and Medical Research Council
Funding Amount
$571,990.00
Summary
Psychiatrists now recognize a pre-symptomatic stage is present in people at risk of developing schizophrenia. Using new brain imaging techniques we now know that some of these individuals have changes in a major neurotransmitter, dopamine, prior to being diagnosed. We have developed a new model in animals, which recreates these exact same changes at a comparable age. We want to now understand what are the broader effects in the brain and try and block these changes in dopamine with new drugs.
Dopamine Neuron Ontogeny: Convergent Neurobiological Pathway For Risk Factors Of Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$337,214.00
Summary
Schizophrenia is associated with changes in dopamine (a signalling molecule in the brain). These changes are present prior to psychosis, suggesting they begin early in development. Our aims are to manipulate key factors in the development of brain dopamine systems to clarify their role in psychosis and schizophrenia. This work has the potential to identify early brain changes that lead to schizophrenia, which in turn may generate better diagnoses and outcomes for people with this disorder.
Developmental Vitamin D Deficiency And Prefrontal Cortical Dysfunction
Funder
National Health and Medical Research Council
Funding Amount
$355,570.00
Summary
The cause of schizophrenia is unknown but is believed to be due to abnormal brain development. Dopamine abnormalities are central to schizophrenia. We have developed a model of maternal vitamin D deficiency in rats, based on disease epidemiology that shows individuals that have low levels of vitamin D at birth have an increased risk of developing schizophrenia later in life. We now also show dopamine systems in regions associated with cognition may develop abnormally in our animal model.
The Developmental Vitamin D-deficiency Animal Model Of Schizophrenia:- Critical Window For Intervention And Optimal Dose
Funder
National Health and Medical Research Council
Funding Amount
$365,811.00
Summary
We have established that low levels of vitamin D at birth increase the risk of children developing schizophrenia in later life. Our studies indicate this risk is dose-dependent and may be enhanced if developmental vitamin D (DVD) deficiency is extended into postnatal life implying there may be an early critical vitamin D threshold and a critical window of exposure required to avert schizophrenia. This project will examine this and the effects of supplements using our DVD-deficiency animal model.
Maternal Vitamin D Supplementation In A Maternal Immune Activation Model Of Schizophrenia: Mechanisms Of Prevention
Funder
National Health and Medical Research Council
Funding Amount
$523,364.00
Summary
Maternal infection and vitamin D deficiency during pregnancy increase the risk of children developing schizophrenia. We model these risk factors in pregnant mice. Offspring produce schizophrenia-like behaviours. When pregnant mice with experimental inflammation are treated with the hormonally active form of vitamin D this completely abolished all schizophrenia-like behaviours in offspring. We want to a) understand this mechanism, b) replicate using a form of vitamin D safe-to-use in humans.
Understanding The Pathophysiology Of Schizophrenia, Major Depressive Disorder And Bipolar Disorder As A Basis For Improving Treatments
Funder
National Health and Medical Research Council
Funding Amount
$804,106.00
Summary
The Applicant seeks to understand the causes of the schizophrenia, bipolar disorder and major depressive disorder, which affect over 20% of the Australian population. This research is important as drug design, based on chemical remodelling, has not significantly advanced initial breakthroughs in treating psychiatric disorders and there is now a widespread belief that new drugs will only come from understand their causes.
Early Pharmacological Intervention In An Animal Model Of Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$438,857.00
Summary
The symptoms of schizophrenia do not appear until late adolescence/early adulthood. Some adolescents may be at “high risk” of progressing to clinical psychosis. There is now intense interest in using antipsychotic drugs (APDs) to delay symptoms in these patients. APD use in adolescents however is controversial. This project seeks to clarify the structural, neurochemical and functional implications of APD use in a well described animal model of schizophrenia, developmental vitamin D deficiency.
Novel Methods To Study Structural-functional Connectivity In Epilepsy And Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$697,605.00
Summary
Magnetic Resonance Imaging (MRI) is a non-invasive method that has revolutionised our understanding of clinical neuroscience. MRI provides not only high-contrast anatomical images, but also information on brain physiology and function. My primary goal is to develop and optimise novel MRI methods for a more accurate measure of brain structure and function. My research program will focus on the application of these methods to the investigation of epilepsy and schizophrenia.
Do The Developmental Vitamin D-deficiency And Maternal Immune Activation Animal Models Of Schizophrenia Have Convergent Early Pathways ?
Funder
National Health and Medical Research Council
Funding Amount
$669,580.00
Summary
The etiology of schizophrenia is unknown but it is generally considered to have a neurodevelopmental basis and involve altered dopamine signaling. Using two distinct developmental animal models of schizophrenia we have shown convergent gestational abnormalities in how dopamine systems develop. This is possibly a convergent early etiological mechanism in schizophrenia.